Regenxbio (RGNX) Misses Q2 EPS by 2c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Regenxbio Inc. (RGNX) PT Lowered to $100 at Chardan Capital Markets, Following Drug Trial Update
August 4, 2020 2:36 PM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Regenxbio Inc. (NASDAQ: RGNX) to $100.00 (from $150.00) while maintaining a Buy rating.
... MoreRegenxbio (RGNX) Announces Additional Positive Interim Phase I/IIa Trial Update and Program Updates for RGX-314 for the Treatment of Wet AMD
August 4, 2020 7:10 AM EDTCompany on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020RGX-314 was generally well-tolerated in 42 patients at all dose levels in Phase I/IIa trialPositive interim update from Cohorts 4 and 5 at one year informs pivotal program Durable treatment effect observed with stable to improved visual acuity and retinal thickness Demonstrated meaningful reductions in anti-VEGF treatment burden over one year 61% and 85% reduction of anti-VEGF injections in Cohorts 4 and 5, respectively73% of patients (8/11) in Cohort 5 remain anti-VEGF... More
